(Q37983690)

26 August 2017

title

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment (English)

1 reference

26 August 2017

1 reference

4

1 reference

26 August 2017

1

Sophie Postel-Vinay

1 reference

26 August 2017

6

Jean-Charles Soria

0 references

Alan Ashworth

series ordinal

5

object named as

Alan Ashworth

1 reference

26 August 2017

3

Ken A Olaussen

1 reference

26 August 2017

Elsa Vanhecke

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

14 February 2012

1 reference

Nature Reviews Clinical Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

144-155

1 reference

26 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

TP53 mutations in nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Role of LKB1 in lung cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Chromosomal and genomic changes in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA repair: from genome maintenance to biomarker and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Cell-cycle checkpoints and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA repair pathways as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

TP53 mutations in human cancers: origins, consequences, and clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Role of DNA mismatch repair defects in the pathogenesis of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Relative frequency and morphology of cancers in carriers of germline TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Quality control by DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Regulation of endonuclease activity in human nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

BRCA gene structure and function in tumor suppression: a repair-centric perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Synthetic lethality: exploiting the addiction of cancer to DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Synthetic lethal approaches to breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

The multifaceted mismatch-repair system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Mechanism and regulation of human non-homologous DNA end-joining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Reduced DNA-dependent protein kinase activity is associated with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA-dependent protein kinase is inhibited by trifluoperazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA repair capacity and lung cancer risk in never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Genetic variation in the DNA repair genes is predictive of outcome in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Regulation of DNA double-strand break repair pathway choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

ERCC1-specific immunostaining in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Expression of mismatch repair proteins, hMLH1/hMSH2, in non-small cell lung cancer tissues and its clinical significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Polymorphism in the hMSH2 gene (gISV12-6T > C) is a prognostic factor in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Expression of DNA mismatch repair gene MSH2 in cytological material from lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.3

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

31 March 2020

1 reference

12 December 2020

Retinoblastoma regulatory pathway in lung cancer

1 reference

12 December 2020

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis

1 reference

12 December 2020

Competitive and noncompetitive inhibition of the DNA-dependent protein kinase

1 reference

12 December 2020

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

1 reference

12 December 2020

Excision repair cross complementing-group 1: gene expression and platinum resistance.

1 reference

12 December 2020

The role of DNA mismatch repair in platinum drug resistance

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCLINONC.2012.3

1 reference

26 August 2017

1 reference